# Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.

> **NCT04703127** · PHASE3 · UNKNOWN · sponsor: **Sohag University** · enrollment: 60 (estimated)

## Conditions studied

- Premature Ejaculation

## Interventions

- **DRUG:** Tadalafil and Combined Dapoxietine
- **DRUG:** Dapoxietine and Combined Lidocaine 5% Spray

## Key facts

- **NCT ID:** NCT04703127
- **Lead sponsor:** Sohag University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-30
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-01-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703127, "Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04703127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*